Status note MLASC (maternal leukocyte and stromal cell) candidate. Filing cites 'encouraging clinical data in Phase 1 and Phase 2 studies' and says the company is selectively advancing programs with a focus on longevity applications. (Note: latest available filing is the 10-Q for the period ended 2025-09-30.)
CYNK-001
Stage not disclosed · ActiveModality: Cell therapy (placental-derived allogeneic NK cells)
Partnerships Dragasac: exclusive distribution and manufacturing agreement covering CYNK-001 (clinical/investigational/near-term commercial products); Genting Innovation: distribution and manufacturing rights incl. CYNK-001
Indications
Aging and other non-oncology indications(Stage not disclosed)
Status note Unmodified natural killer cell therapy. Filing references unmodified NK cell clinical trials under a contingent consideration agreement with Anthrogenesis; current clinical phase not stated in the 10-Q excerpts.
PSC-100
Stage not disclosed · ActiveModality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications
Regenerative indications(Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
PDA-001
Stage not disclosed · ActiveModality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications
Regenerative indications(Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
PDA-002
Stage not disclosed · ActiveModality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications
Regenerative indications(Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
pEXO-001
Stage not disclosed · ActiveModality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications
Regenerative indications(Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
APPL-001
Stage not disclosed · ActiveModality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications
Regenerative indications(Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
Per-asset detail extracted from the 10-Q filed 2025-11-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.